echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sprinting into the 1.9 billion injection market, Sinopharm Group's application for doxofylline injection was accepted

    Sprinting into the 1.9 billion injection market, Sinopharm Group's application for doxofylline injection was accepted

    • Last Update: 2022-04-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Sinopharm Group has been accepted by CDE for its marketing application for doxofylline injection, which is a generic type 4 application, which is used to treat bronchitis and other diseases


    Doxofylline is a derivative of methylxanthine.


    According to data from Minet.


    Sales of terminal doxofylline injection in Chinese public medical institutions (unit: ten thousand yuan)

    Source: Minet.


    Up to now, doxofylline injection has been reviewed by 14 companies, including Fuhe Pharmaceutical, Fuan Pharmaceutical, Yangzijiang, Shijiazhuang No.


    Data source: Minet database

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.